| __timestamp | Alnylam Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 5280000 |
| Thursday, January 1, 2015 | 276495000 | 7148000 |
| Friday, January 1, 2016 | 382392000 | 19594000 |
| Sunday, January 1, 2017 | 390635000 | 22894000 |
| Monday, January 1, 2018 | 505420000 | 50337000 |
| Tuesday, January 1, 2019 | 655114000 | 109450000 |
| Wednesday, January 1, 2020 | 654819000 | 90450000 |
| Friday, January 1, 2021 | 792156000 | 104128000 |
| Saturday, January 1, 2022 | 883015000 | 108630000 |
| Sunday, January 1, 2023 | 1004415000 | 134951000 |
| Monday, January 1, 2024 | 1126232000 |
Data in motion
In the competitive landscape of biopharmaceuticals, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Alnylam Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D expenditures.
Since 2014, Alnylam has consistently increased its R&D spending, culminating in a 428% rise by 2023. This strategic investment underscores their commitment to pioneering RNA interference therapeutics, positioning them as a leader in the field.
Conversely, Rhythm Pharmaceuticals has shown a more modest growth in R&D investments, with a 2,456% increase over the same period. This reflects their focused approach on rare genetic disorders, aiming to bring targeted therapies to market.
These investment patterns highlight the diverse strategies within the biopharmaceutical industry, where innovation is driven by both expansive and targeted R&D efforts.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Rhythm Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sanofi and Rhythm Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Axsome Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. or Wave Life Sciences Ltd.: Who Invests More in Innovation?
United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc.
R&D Spending Showdown: Rhythm Pharmaceuticals, Inc. vs Veracyte, Inc.
Rhythm Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs MannKind Corporation
Research and Development Investment: Rhythm Pharmaceuticals, Inc. vs Evotec SE